Also CT is used as a systemic therapy in patients with node-positive HER2-positive or triple-negative breast cancer and with N2/N3 disease of hormone receptor (HR)-positive and HER2-negative breast cancer. Here, ERBB2 is linked to triple-negative breast carcinoma.